November 20, 2024

 

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention:		Tamika N. Sheppard
Re:		Gyre Therapeutics, Inc.
		Registration Statement on Form S-3 (File No. 333-283237)

Ladies and Gentlemen:

 

Gyre Therapeutics, Inc. hereby respectfully requests that, pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, the effectiveness of the above-referenced Registration Statement on Form S‑3 be accelerated so that it will become effective on November 22, 2024, at 4:15 p.m., Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time.

 

We request that we be notified of such effectiveness by a telephone call to Branden C. Berns of Gibson, Dunn & Crutcher at (415) 393-4631.